Cell therapy weekly: new CAR-T therapy triples remission time for multiple myeloma patients

This week: an international trial has reported that a new type of CAR-T therapy more than triples the expected length of remission for patients with multiple myeloma, Kymriah™ becomes the first commercial CAR-T therapy in Singapore, bluebird bio provides updated findings from its Phase I/II study of LentiGlobin gene therapy for sickle cell disease, and the US FDA has granted an RMAT designation to RP-L201, which is an investigational gene therapy for the treatment of leukocyte adhesion deficiency-I. The news highlights: New CAR-T therapy triples remission time for multiple myeloma patients Kymriah™ becomes the first commercially approved CAR-T therapy in...